Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 60, Issue 10, 2005, Pages 1301-1307

  Reinartz, Susanne M ^a   Overbeek, S E ^b   KleinJan, A ^b   Van Drunen, C M ^b   Braunstahl, G J ^b   Hoogsteden, H C ^b   Fokkens, W J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Allergic inflammation; Asthma; Desloratadine; Eosinophils; Nasal provocation; Rhinitis

Indexed keywords

ANTIHISTAMINIC AGENT; DESLORATADINE; EOTAXIN; INTERLEUKIN 5; METHACHOLINE; PLACEBO; POLLEN ANTIGEN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; BRONCHUS BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NASAL BIOPSY; PEAK EXPIRATORY FLOW; PRICK TEST; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VISUAL ANALOG SCALE;

ADULT; ASTHMA; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; INFLAMMATION; LORATADINE; MALE; NASAL PROVOCATION TESTS; POACEAE; POLLEN; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 24744453511     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2005.00911.x     Document Type: Article

References (24)

1. Bousquet J, Vignola AM, Demoly P. Links between rhinitis and asthma. Allergy 2003;58:691-706.
2. Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. J All Clin Immunol 2001;107:469-476.
3. Braunstahl GJ, Kleinjan A, Overbeek SE, Prins JB, Hoogsteden HC, Fokkens WJ. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000;161:2051-2057.
4. Denburg JA, Inman MD, Leber B, Sehmi R, O'byrne PM. The role of bone marrow in allergy and asthma. Allergy 1996;51:141-148.
5. Van Ganse E, Kaufman L, Derde MP, Yernault JC, Delaunois L, Vincken W. Effects of antihistamines in adult asthma: a meta-analysis of clinical trials. Eur Respir J 1997;10:2216-2224.
6. Wilson AM, Haggart K, Sims EJ, Lipworth BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp All 2002;32:1504-1509.
7. Horak F, Stubner UP, Zieglmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J All Clin Immunol 2002;109:956-961.
8. Baena-Cagnani CE. Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001;65(Suppl. 56):21-27.
9. Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann All Asthma Immunol 2002;89:485-491.
10. DiGioacchino M, Verna N, Cavallucci E, Paolini F, Caruso R, Grana M et al. Steroid and antihistamines modulate RANTES release in cultured peripheral blood mononuclear cells of atopic patients. Int J Immunopathol Pharmacol 2002;15:27-34.
11. Henz BM. The pharmacologic profile of desloratadine: a review. Allergy 2001;65(Suppl. 56):7-13.
12. Genovese A, Patella V, Decrescenzo G, Depaulis A, Spadaro G, Marone G. Loratadine and desethoxylcarbonylloratadine inhibit the immunological release of mediators from human Fc epsilon RI + cells. Clin Exp All 1997;27:559-567.
13. Bryce PJ, Geha R, Oettgen HC. Desloratadine inhibits allergen-induced airway inflammation and bronchial hyperresponsiveness and alters T-cell responses in murine models of asthma. J All Clin Immunol 2003;112:149-158.
14. Gelfand EW. Role of histamine in the pathophysiology of asthma: immunomodulatory and anti-inflammatory activities of H1-receptor antagonists. Am J Med 2002;9A(Suppl. 113):2S-7S.
15. Fasce L, Ciprandi G, Pronzato C, Cozzani S, Tosca MA, Grimaldi I et al. Cetirizine reduces ICAM-I on epithelial cells during nasal minimal persistent inflammation in asymptomatic children with mite-allergic asthma. Int Arch All Immunol 1996;109:272-276.
16. Hargreave FE, Ramsdale EH, Sterk PJ, Juniper EF. Advances in the use of inhalation provocation tests in clinical evaluation. Chest 1985;87(Suppl. 1): 32S-35S.
17. Godthelp T, Holm AF, Fokkens WJ, Doornenbal P, Mulder PG, Hoefsmit EC et al. Dynamics of nasal eosinophils in response to a nonnatural allergen challenge in patients with allergic rhinitis and control subjects: a biopsy and brush study. J All Clin Immunol 1996;97:800-811.
18. Braunstahl GJ, Fokkens W. Nasal involvement in allergic asthma. Allergy 2003;58:1235-1243.
19. Feather I, Wilson S. Eosinophils in rhinitis. In: Busse W, Holgate S, editors. Asthma and rhinitis, 1st edn. Oxford: Blackwell Scientific Publications, 1995:347-363.
20. Kowalski ML, Lewandowska A, Wozniak J, Makowska J, Jankowski A, Dubuske L. Inhibition of nasal polyp mast cell and eosinophil activation by desloratadine. Allergy 2005;60:80-85.
21. Bousquet J, VanCauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J All Clin Immunol 2001;108(Suppl. 5):S147-S334.
22. Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001;56:14-20.
23. Aubier M, Neukirch C, Peiffer C, Melac M. Effect of cetirizine on bronchial hyperresponsiveness in patients with seasonal allergic rhinitis and asthma. Allergy 2001;56:35-42.
24. Bousquet J, Bindslev-Jensen C, Canonica GW, Fokkens W, Kim H, Kowalski ML et al. The ARIA/EAACI criteria for antihistamines:an assessment of the efficacy, safety and pharmacology of desloratadine. Allergy 2004;59(Suppl. 77):4-16.